People · Operator
Named in public records as an officer, director or promoter · active 2015–2021 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Amunix Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $203.9M | $3.9B | 2021 |
| Metacrine, Inc. | — | Pharmaceuticals | Series C | $124.8M | $2.3B | 2015 |
Trisha Millican at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Trisha Millican on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard Heyman | 2 | 2 |
| David Hirsch | 1 | 16 |
| Kristina Burow | 1 | 16 |
| Amir Nashat | 1 | 14 |
| James Topper | 1 | 12 |
| Carol Gallagher | 1 | 6 |
| Robert Adelman | 1 | 5 |
| Otello Stampacchia | 1 | 4 |
| Neil McDonnell | 1 | 4 |
| Ronald Evans | 1 | 2 |
| Kenneth Song | 1 | 2 |
| Volker Schellenberger | 1 | 2 |
| Angie You | 1 | 2 |
| Ken Song | 1 | 2 |
| Patricia Millican | 1 | 1 |
| Jackie Hernandez | 1 | 1 |
| James Brush | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.